Faisal Khurshid
Stock Analyst at Leerink Partners
(0)
# 4793
Out of 5,337 analysts
20
Total ratings
23.08%
Success rate
-22.47%
Average return
Main Sectors:
Top Industries:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
IRWD Ironwood Pharmaceuti... | Maintains: Market Perform | 3 1 | 0.64 | 56.25% | 2 | Apr 14, 2025 | |
SYRE Spyre Therapeutics | Initiates Coverage On: Outperform | 45 | 14.81 | 203.85% | 1 | Apr 8, 2025 | |
NRIX Nurix Therapeutics | Initiates Coverage On: Market Perform | 16 | 9.59 | 66.84% | 1 | Mar 17, 2025 | |
STTK Shattuck Labs | Initiates Coverage On: Outperform | 4 | 0.89 | 349.44% | 1 | Mar 17, 2025 | |
PLRX Pliant Therapeutics | Downgrades: Market Perform | 33 2 | 1.38 | 44.93% | 2 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 16 | 3.04 | 426.32% | 1 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 60 60 | 29.76 | 101.61% | 2 | Dec 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 80 | 60.23 | 32.82% | 1 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 15 | 1.18 | 1171.19% | 1 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Outperform | 7 | 6.25 | 12% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Outperform | 45 | 16.72 | 169.14% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Market Perform | 24 | 26.43 | -9.19% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 7 | 1.19 | 488.24% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Outperform | 8 | 4.58 | 74.67% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Outperform | 5 | 0.98 | 410.2% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Market Perform | 17 21 | n/a | n/a | 1 | Mar 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 11 | 5.66 | 94.35% | 1 | Mar 21, 2023 |